天然痘治療市場- 世界の産業規模、シェア、動向、機会、予測、治療の種類別、製品タイプ別、エンドユーザー別、地域別、競合別、2020～2030年

天然痘治療の世界市場は、2024年には7,456万米ドルとなり、予測期間中のCAGRは3.71%で、2030年には7,799万米ドルに達すると予測されています。

天然痘治療の世界市場は最近の動向で大きな進展を見せており、この壊滅的なウイルス性疾患との闘いにおいて有望な時代を迎えています。かつて世界の健康脅威であった天然痘は、広範なワクチン接種キャンペーンのおかげで1980年に根絶が宣言されました。しかし、天然痘がバイオテロの脅威として再来する可能性や、関連するポックスウイルスの出現が懸念され、効果的な治療法の必要性が再燃しています。2024年10月22日に更新されたCDCのデータによれば、天然痘は根絶され、1977年以降、症例は報告されていないです。この病気は発疹を特徴とし、咳やくしゃみによって感染しました。天然痘はもはや自然発生しないが、生物学的攻撃でバリオラウイルスが使用される潜在的リスクは残っています。その可能性は低いが、公衆衛生当局は、生物兵器としての天然痘の脅威の可能性に対処するため、引き続き準備対策を実施しています。

天然痘は、バリオラウイルスによって引き起こされ、非常に感染力が強く、しばしば死に至る病気で、何世紀にもわたって人類を悩ませてきました。数え切れないほどの死者と広範な苦しみをもたらしました。幸いなことに、ワクチン接種プログラムの成功により、世界保健機関（WHO）は1980年に天然痘の根絶を宣言しました。しかし、天然痘ウイルスは、現在も2カ所の研究所に備蓄されており、悪用される可能性が懸念されています。世界の天然痘治療市場は、こうした懸念に対応して発展してきました。研究開発の努力により、天然痘が発生した場合に有望な抗ウイルス薬やワクチンが開発されました。天然痘がバイオテロとして使用される可能性への認識が高まったことで、治療法の研究開発への投資が活発化しました。各国政府や国際機関は、備えを確実にするために積極的に取り組んでいます。分子生物学とゲノミクスの開発により、バリオラウイルスの複製を阻害する標的型抗ウイルス薬の開発が可能になり、より効果的な治療法が提供されるようになりました。国際的な協力は、天然痘の潜在的な流行に対処するための資源と知識を結集する上で、極めて重要な役割を果たしてきました。WHOや疾病対策予防センター（CDC）のような組織が、こうした取り組みの最前線にいます。

市場促進要因

バイオテロの脅威の増大が世界の天然痘治療市場を牽引

主な市場課題

高い開発コスト

主な市場動向

天然痘治療の世界市場を牽引する技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の天然痘治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療の種類別（抗ウイルス薬、ワクチン接種、支持療法）
  • 製品タイプ別（ワクチン、抗ウイルス薬）
  • エンドユーザー別（病院・診療所、外来診療センター、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米の天然痘治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の天然痘治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の天然痘治療市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の天然痘治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの天然痘治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収（ある場合）
• 製品の発売（ある場合）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Bavarian Nordic A/S
• Chimerix, Inc.
• Pfizer Inc.
• Sanofi SA
• GlaxoSmithKline plc
• Novartis AG
• Johnson & Johnson
• SIGA Technologies, Inc.
• BioCryst Pharmaceuticals, Inc.
• Bharat Biotech International Ltd.

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Smallpox Treatment Market was valued at USD 74.56 Million in 2024 and is expected to reach USD 77.99 Million by 2030 with a CAGR of 3.71% during the forecast period. The global smallpox treatment market has witnessed significant developments in recent years, marking a promising era in the battle against this devastating viral disease. Smallpox, once a global health threat, was declared eradicated in 1980, thanks to widespread vaccination campaigns. However, concerns about the potential re-emergence of smallpox as a bioterrorism threat and the emergence of related poxviruses have reignited the need for effective treatments. As per CDC data updated on October 22, 2024, smallpox has been eradicated, with no reported cases since 1977. The disease, characterized by rashes, was transmitted through coughing and sneezing. While smallpox no longer occurs naturally, there remains a potential risk of the variola virus being used in a biological attack. Although the likelihood is low, public health authorities continue to implement preparedness measures to address the possible threat of smallpox as a bioweapon.

Smallpox, caused by the variola virus, is a highly contagious and often fatal disease that plagued humanity for centuries. It was responsible for countless deaths and widespread suffering. Fortunately, due to the success of vaccination programs, the World Health Organization (WHO) declared smallpox eradicated in 1980. However, the virus still exists in two known laboratory stockpiles, raising concerns about potential misuse. The global smallpox treatment market has evolved in response to these concerns. Research and development efforts have led to the creation of antiviral drugs and vaccines that hold promise in the event of a smallpox outbreak. The increased awareness of the potential use of smallpox as a bioterrorism agent has spurred investments in research and development of treatments. Governments and international organizations are actively working to ensure preparedness. Advances in molecular biology and genomics have enabled the development of targeted antiviral drugs that can inhibit the replication of the variola virus, offering more effective treatment options. International collaboration has played a crucial role in pooling resources and knowledge to tackle potential smallpox outbreaks. Organizations like the WHO and the Centers for Disease Control and Prevention (CDC) are at the forefront of these efforts.

Key Market Drivers

Increasing Bioterrorism Threat is Driving the Global Smallpox Treatment Market

The growing concern over bioterrorism has significantly fueled the expansion of the global smallpox treatment market. Smallpox, once eradicated, remains a potential biological weapon due to its high transmissibility and fatality rate. Governments worldwide, along with international health organizations, are investing heavily in research, development, and stockpiling of smallpox vaccines and antiviral treatments as a precautionary measure. The fear that smallpox could be weaponized in a bioterror attack has led to strategic collaborations between governments, pharmaceutical companies, and research institutions, accelerating the market's growth.

Advancements in biotechnology and genetic engineering have enabled scientists to develop next-generation vaccines and antiviral treatments, enhancing preparedness against potential smallpox outbreaks. Research is focused on developing safer and more effective vaccines with fewer side effects, making them viable for mass immunization in case of emergency. Antiviral drugs targeting the variola virus are undergoing clinical trials to expand treatment options beyond vaccines. National security agencies have also played a vital role in bolstering smallpox preparedness efforts. Countries such as the United States have allocated substantial budgets to smallpox-related biodefense initiatives, supporting the procurement of medical countermeasures. Governments are proactively stockpiling vaccines, ensuring sufficient supplies in the event of an attack. On

Key Market Challenges

High Development Costs

The development of smallpox treatment products, including vaccines and antiviral drugs, requires substantial financial investment due to the complexity of research, clinical trials, and regulatory compliance. Smallpox, as a Category A bioterrorism agent, necessitates stringent biosafety measures, which further drive up costs. Developing vaccines and antiviral drugs involves extensive preclinical and clinical trials to ensure efficacy and safety, requiring significant funding from pharmaceutical companies, government agencies, and global health organizations.

One of the major financial burdens is the long research and development (R&D) timeline. Since smallpox is eradicated, traditional large-scale human clinical trials are not feasible, necessitating alternative pathways such as animal models and immune response studies, which increase expenses. Stringent regulatory requirements from agencies like the FDA, EMA, and WHO mandate extensive documentation and safety assessments before approval, prolonging the time-to-market and adding to costs.

Manufacturing smallpox treatments requires high-containment biosafety laboratories, further inflating operational expenses. Pharmaceutical companies must invest in specialized facilities and bioprocessing technologies to prevent viral exposure and contamination. Given the low commercial demand for smallpox treatments-since the disease is not naturally occurring-companies find it difficult to justify continued investment in research, making government and defense contracts the primary sources of funding. Ultimately, the high cost of development limits market entry for new players, leading to reduced competition and slower innovation. Without continued financial incentives or government-backed initiatives, pharmaceutical companies may deprioritize smallpox treatment development, potentially weakening global preparedness for future outbreaks.

Key Market Trends

Technological Advancements Driving the Global Smallpox Treatment Market

Technological advancements continue to revolutionize the healthcare sector, and their impact on the Global Smallpox Treatment Market has been particularly significant. With growing concerns over the potential re-emergence of smallpox as a bioterrorism threat, the development of innovative vaccines, antiviral treatments, and diagnostic tools has gained momentum. These advancements have enhanced the preparedness of governments and healthcare organizations to respond swiftly in case of an outbreak. One of the key breakthroughs in smallpox treatment is the development of next-generation vaccines. Traditional smallpox vaccines, such as those based on live vaccinia virus, have been effective but are associated with certain safety risks. Modern vaccine technologies, including DNA vaccines, recombinant vaccines, and viral vector-based platforms, are being explored to provide enhanced immunity with fewer side effects. These new-generation vaccines offer better safety profiles and can be mass-produced quickly, making them crucial for emergency preparedness.

Alongside vaccine development, antiviral drug research has also progressed significantly. The introduction of new smallpox antiviral agents, such as tecovirimat and brincidofovir, has expanded treatment options. These drugs work by targeting the replication mechanisms of the Variola virus, reducing disease severity and improving patient outcomes. Continued research into broad-spectrum antiviral drugs is further strengthening treatment options.

The field of diagnostics has also benefited from technological advancements. Polymerase chain reaction (PCR)-based assays and next-generation sequencing (NGS) have enabled rapid and accurate detection of smallpox infections. These tools are vital for early diagnosis and containment strategies. Advancements in biosensors and point-of-care diagnostic devices allow for quicker screening in potential outbreak scenarios. Biotechnology has played a crucial role in smallpox research, leading to the development of monoclonal antibodies and targeted therapies capable of neutralizing the virus. As technological innovations continue to evolve, they will remain central to strengthening the global response against smallpox threats.

Key Market Players

• Bavarian Nordic A/S
• Chimerix, Inc.
• Pfizer Inc.
• Sanofi SA
• GlaxoSmithKline plc
• Novartis AG
• Johnson & Johnson
• SIGA Technologies, Inc.
• BioCryst Pharmaceuticals, Inc.
• Bharat Biotech International Ltd

Report Scope:

In this report, the Global Smallpox Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Smallpox Treatment Market, By Treatment Type:

• Antiviral Drugs
• Vaccination
• Supportive Care

Smallpox Treatment Market, By Product Type:

• Vaccines
• Antiviral Drugs

Smallpox Treatment Market, By End user:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Smallpox Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Smallpox Treatment Market.

Available Customizations:

Global Smallpox Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Smallpox Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Antiviral Drugs, Vaccination, Supportive Care)
  • 5.2.2. By Product Type (Vaccines, Antiviral Drugs)
  • 5.2.3. By End user (Hospitals & Clinics, Ambulatory Care Centers, Others),
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Smallpox Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By Product Type
  • 6.2.3. By End user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Smallpox Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By Product Type
      • 6.3.1.2.3. By End user
  • 6.3.2. Canada Smallpox Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By Product Type
      • 6.3.2.2.3. By End user
  • 6.3.3. Mexico Smallpox Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By Product Type
      • 6.3.3.2.3. By End user

7. Europe Smallpox Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By Product Type
  • 7.2.3. By End user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Smallpox Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By Product Type
      • 7.3.1.2.3. By End user
  • 7.3.2. United Kingdom Smallpox Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By Product Type
      • 7.3.2.2.3. By End user
  • 7.3.3. Italy Smallpox Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By Product Type
      • 7.3.3.2.3. By End user
  • 7.3.4. France Smallpox Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By Product Type
      • 7.3.4.2.3. By End user
  • 7.3.5. Spain Smallpox Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By Product Type
      • 7.3.5.2.3. By End user

8. Asia-Pacific Smallpox Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Product Type
  • 8.2.3. By End user
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Smallpox Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Product Type
      • 8.3.1.2.3. By End user
  • 8.3.2. India Smallpox Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Product Type
      • 8.3.2.2.3. By End user
  • 8.3.3. Japan Smallpox Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Product Type
      • 8.3.3.2.3. By End user
  • 8.3.4. South Korea Smallpox Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment Type
      • 8.3.4.2.2. By Product Type
      • 8.3.4.2.3. By End user
  • 8.3.5. Australia Smallpox Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment Type
      • 8.3.5.2.2. By Product Type
      • 8.3.5.2.3. By End user

9. South America Smallpox Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Product Type
  • 9.2.3. By End user
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Smallpox Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Product Type
      • 9.3.1.2.3. By End user
  • 9.3.2. Argentina Smallpox Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Product Type
      • 9.3.2.2.3. By End user
  • 9.3.3. Colombia Smallpox Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Product Type
      • 9.3.3.2.3. By End user

10. Middle East and Africa Smallpox Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By Product Type
  • 10.2.3. By End user
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Smallpox Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By Product Type
      • 10.3.1.2.3. By End user
  • 10.3.2. Saudi Arabia Smallpox Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By Product Type
      • 10.3.2.2.3. By End user
  • 10.3.3. UAE Smallpox Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By Product Type
      • 10.3.3.2.3. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Bavarian Nordic A/S
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Chimerix, Inc.
• 14.3. Pfizer Inc.
• 14.4. Sanofi SA
• 14.5. GlaxoSmithKline plc
• 14.6. Novartis AG
• 14.7. Johnson & Johnson
• 14.8. SIGA Technologies, Inc.
• 14.9. BioCryst Pharmaceuticals, Inc.
• 14.10. Bharat Biotech International Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer